Funding
← Back to your selection

Canaan Partners

Activity from announced rounds

Activity in this selectionOct 24, 2026 · Biotech · Jan 1, 2026

Canaan Partners is an investment firm whose company directory identifies Draig Therapeutics and Solstice Oncology.

Recorded funding activity

Draig develops neuropsychiatric medicines, while Solstice advances an engineered CTLA-4 antibody for cancer treatment. The recorded history also includes Actualyze AI’s enterprise gateway for model access, request security, budgets and routing. Named regional funds retain separate identities.

Sources
Rounds participated in
3
Confirmed lead rounds
0
2 roles undisclosed
New companies
3
First participation on record · 0 follow-on
Funding in participating rounds
$336M
3 disclosed · full round size, not this investor’s share

By stage

Series A2
Series B1

By primary sector

Biotech3

By country

United States2
United Kingdom1

Rounds

3 in this selection
Solstice Oncology

A clinical-stage immunotherapy company is advancing an engineered CTLA-4 antibody for earlier cancer treatment.

$225MSeries A
Participant